Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
Nakajima TE, Boku N, Doi A, Arai H, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Sunakawa Y. Nakajima TE, et al. Among authors: mizukami t. Invest New Drugs. 2020 Apr;38(2):410-418. doi: 10.1007/s10637-019-00782-8. Epub 2019 Apr 24. Invest New Drugs. 2020. PMID: 31020609 Clinical Trial.
Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.
Horie Y, Yamazaki K, Funakoshi T, Hamauchi S, Taniguchi H, Tsushima T, Todaka A, Machida N, Taku K, Fukutomi A, Onozawa Y, Yasui H, Mizukami T, Izawa N, Hirakawa M, Tsuda T, Nakajima T, Boku N. Horie Y, et al. Among authors: mizukami t. Mol Clin Oncol. 2015 Sep;3(5):1029-1034. doi: 10.3892/mco.2015.586. Epub 2015 Jun 24. Mol Clin Oncol. 2015. PMID: 26623045 Free PMC article.
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K. Mizukami T, et al. Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24. Mol Carcinog. 2017. PMID: 26916220
Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T, Kyomori C, Mizukami T, Taniyama T, Izawa N, Horie Y, Hirakawa M, Ogura T, Nakajima TE, Tsugawa K, Boku N. Tsuda T, et al. Among authors: mizukami t. Mol Clin Oncol. 2016 Apr;4(4):603-606. doi: 10.3892/mco.2016.769. Epub 2016 Feb 5. Mol Clin Oncol. 2016. PMID: 27073673 Free PMC article.
Identification of a FGFR3-TACC3 fusion in esophageal cancer.
Mizukami T, Sakai K, Naruki S, Taniyama T, Horie Y, Izawa N, Tsuda T, Fujino T, Boku N, Yasuda H, Fukunaga T, Nakajima TE, Nishio K. Mizukami T, et al. Ann Oncol. 2017 Feb 1;28(2):437-438. doi: 10.1093/annonc/mdw550. Ann Oncol. 2017. PMID: 27771611 Free article. No abstract available.
Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy.
Shigefuku R, Watanabe T, Mizukami T, Matsunaga K, Hattori N, Ehira T, Suzuki T, Nakano H, Sato Y, Matsuo Y, Nakahara K, Ikeda H, Matsumoto N, Tsuda T, Katayama M, Koizumi S, Okuse C, Suzuki M, Otsubo T, Nakajima TE, Yasuda H, Itoh F. Shigefuku R, et al. Among authors: mizukami t. Clin J Gastroenterol. 2018 Dec;11(6):487-492. doi: 10.1007/s12328-018-0873-1. Epub 2018 Jun 11. Clin J Gastroenterol. 2018. PMID: 29948819
568 results